The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
E. Daly, Ibrahim Turkoz, Giacomo Salvadore, Maggie Fedgchin, Dawn F. Ionescu, H. Starr, Stephane Borentain, Madhukar H. Trivedi, Michael E. Thase, Jaskaran Singh
Depression and Anxiety July 22, 2021 DOI: 10.1002/da.23193 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Post hoc analysis Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression with or without comorbid anxiety |
| Interventions | Esketamine antidepressant |
| Topics | Anxiety Depression Esketamine |
| Key points | Esketamine plus an antidepressant improved depressive symptoms more than an antidepressant alone in treatment-resistant depression patients with comorbid anxiety. |
Abstract
Comorbid anxiety is generally associated with poorer response to antidepressant treatment. This post hoc analysis explored the efficacy of esketamine plus an antidepressant in patients with treatment‐resistant depression (TRD) with or without comorbid anxiety.
Comparable studies
Other observational and cohort studies on esketamine for anxiety, most cited first.